DoD Duchenne Muscular Dystrophy, Translational Research Award | W81XWH 22 DMDRP TRA

FY22 DoD Duchenne Muscular Dystrophy (DMD) Translational Research Award (TRA) FAQs

1) What is the FY22 DMDRP Translational Research Award (TRA)?

The FY22 DoD Duchenne Muscular Dystrophy, Translational Research Award (FY22 DMDRP TRA) is a Department of Defense funding opportunity intended to move Duchenne muscular dystrophy (DMD) research beyond basic science and closer to real-world clinical use. The focus is on translational research that deliberately connects laboratory findings with clinical observations and patient-focused insights to help advance a therapy, device, or intervention toward practical clinical application with near-term impact.

2) What does the program mean by "translational research"?

Under this opportunity, translation is described as an active, two-way exchange rather than a simple one-direction path from bench to bedside. Clinical needs and patient data should inform the laboratory work, and laboratory findings should guide clinical strategy. The proposal is expected to show how the project will integrate clinical and patient-relevant insights with the research plan.

3) What kinds of projects are most aligned with the intent of this award?

The mechanism is aimed at established projects that already have momentum and are not purely exploratory. It emphasizes moving a promising concept, therapeutic approach, device, or intervention toward practical clinical application, with an emphasis on near-term impact.

4) Are preliminary data required?

Yes. Applications must include preliminary data that is directly relevant to Duchenne muscular dystrophy (DMD) and to the specific approach being proposed. This indicates the program is not intended for early speculative concepts without supporting evidence.

5) Does the award support clinical trials?

Yes. The program allows pilot and proof-of-principle clinical trials. It also allows correlative studies that can clarify how and why a therapy works, identify biomarkers, refine patient selection, or otherwise strengthen the development pathway for drugs, devices, or other interventions.

6) What are "correlative studies" in the context of this opportunity?

Based on the description provided, correlative studies are studies linked to the intervention or trial that help explain mechanism of action, identify or validate biomarkers, improve patient selection, and strengthen the overall translational development pathway for the therapy, device, or intervention.

7) Is the award focused only on pediatric DMD?

No. The opportunity explicitly encourages research on therapies that can work across the lifespan and highlights particular interest in approaches that address the needs of adolescents and adults, groups that have historically had fewer tailored therapeutic options in DMD.

8) Does the proposal need to address relevance to the military?

Yes. A key requirement is that the proposed work be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the broader American public. Applicants are expected to clearly explain the public and military relevance and potential benefit of the work.

9) Is this funding offered as a grant or a cooperative agreement?

The funding instrument types include both grants and cooperative agreements. This indicates that, depending on the project structure, some awards may involve more substantial involvement or oversight by the sponsoring agency.

10) Who administers this funding opportunity?

The opportunity is administered by the Department of Defense (Department of the Army, USAMRAA).

11) What is the Funding Opportunity Number for this award?

The Funding Opportunity Number is W81XWH-22-DMDRP-TRA.

12) What is the CFDA number associated with this program?

The CFDA number listed for this opportunity is 12.420.

13) Who is eligible to apply?

Eligibility is described as unrestricted, meaning a wide range of organizations may apply, as long as they meet any additional conditions described in the full announcement.

14) What is the Early-Career Partnering PI Option?

The FY22 TRA includes an Early-Career Partnering PI Option intended to promote meaningful collaboration and strengthen the DMD research pipeline. Under this option, two principal investigators can be formally integrated into the application: an Initiating PI and an Early-Career Partnering PI.

15) What is the difference between the Initiating PI and the Early-Career Partnering PI?

The Initiating PI manages most submission and administrative responsibilities. The Early-Career Partnering PI is expected to play a substantive scientific role. The expectation is that both investigators contribute significantly to the design and execution of the study, including major components such as the project narrative and statement of work.

16) If funded under the Early-Career Partnering PI Option, how are the PIs recognized?

If funded, each PI is recognized on a separate award under the recipient organization. This structure is intended to reflect a real and professionally meaningful partnership rather than a symbolic role.

17) When was this funding opportunity created and when did it close?

The opportunity was created on June 6, 2022. The original closing date was November 15, 2022.

18) How many awards were anticipated?

The opportunity anticipated making about two awards.

19) What is the maximum award amount (ceiling)?

The award ceiling is shown as 0 in the source data summary. This typically means applicants should rely on the full announcement for budget limits or that the ceiling was not specified in that summary field.

20) Is this award intended for early, high-risk speculative ideas?

No. The opportunity is described as targeting established projects with momentum and requires DMD- and approach-relevant preliminary data, signaling it is not intended for early speculative concepts without supporting evidence.